BriaCell Therapeutics Corp.
BCT.TO
TSX
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.98% | -8.83% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.19% | -9.51% | |||
| Operating Income | -1.19% | 9.51% | |||
| Income Before Tax | 0.82% | 11.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 0.82% | 11.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -3.46% | -7.05% | |||
| Net Income | 0.79% | 11.90% | |||
| EBIT | -1.19% | 9.51% | |||
| EBITDA | -1.11% | 9.54% | |||
| EPS Basic | 61.66% | 40.78% | |||
| Normalized Basic EPS | 61.65% | 41.44% | |||
| EPS Diluted | 61.63% | 40.71% | |||
| Normalized Diluted EPS | 61.65% | 41.44% | |||
| Average Basic Shares Outstanding | 158.73% | 48.75% | |||
| Average Diluted Shares Outstanding | 158.73% | 48.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||